Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
+0.04 (0.56%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.96 - 7.38
52 week 6.36 - 10.32
Open 7.20
Vol / Avg. 891,046.00/1.05M
Mkt cap 471.38M
P/E     -
Div/yield 0.15
EPS -1.00
Shares 65.29M
Beta 2.19
Inst. own 68%
Jun 27, 2014
Spectrum Pharmaceuticals Inc Annual Shareholder Meeting - 1:30PM EDT - Add to calendar
Mar 11, 2014
Spectrum Pharmaceuticals Inc at ROTH Conference
Mar 6, 2014
Q4 2013 Spectrum Pharmaceuticals Inc Earnings Conference Call - Webcast
Mar 6, 2014
Q4 2013 Spectrum Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -94.84% -39.87%
Operating margin -15.69% -24.89%
EBITD margin - 2.17%
Return on average assets -33.15% -12.38%
Return on average equity -54.11% -21.80%
Employees 226 -
CDP Score - -


SUITE 240, 11500 S. EASTERN AVE.,
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Joseph Turgeon President, Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Brett L. Scott CPA Senior Vice President - Finance
Age: 62
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 59
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Director
Age: 72
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 55
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 77
Bio & Compensation  - Reuters
Anthony E. Maida Ph.D., III Independent Director
Age: 61
Bio & Compensation  - Reuters